709 844
of biochemical recurrence after radical prostatectomy. Eur Urol
2010;57:562–8
.
[7]
Halverson S, Schipper M, Blas K, et al. The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radia- tion therapy: evaluation and optimization in patients at higher risk of relapse. Radiother Oncol 2011;101:513–20.
[8]
Ishizaki F, Hoque MA, Nishiyama T, et al. External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy. Jpn J Clin Oncol 2011;41:1259–64.[9]
Tamblyn DJ, Chopra S, Yu C, Kattan MW, Pinnock C, Kopsaftis T. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer. BJU Int 2011;108(Suppl 2):51–6.[10]
Buda¨us L, Isbarn H, Tennstedt P, et al. Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients. BJU Int 2012;110:1714–20.[11]
Yoshida T, Nakayama M, Takeda K, Arai Y, Kakimoto K-I, Nishimura K. External validation of the cancer of the prostate risk assessment score to predict biochemical relapse after radical prostatectomy for prostate cancer in Japanese patients. Urol Int 2012;89:45–51.[12]
Krishnan V, Delouya G, Bahary J-P, Larrive´e S, Taussky D. The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with ex- ternal beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy. BJU Int 2014;114:865–71.[13]
Seo WI, Kang PM, Kang DI, Yoon JH, Kim W, Chung JI. Cancer of the Prostate Risk Assessment (CAPRA) preoperative score versus post- operative score (CAPRA-S): ability to predict cancer progression and decision-making regarding adjuvant therapy after radical pros- tatectomy. J Korean Med Sci 2014;29:1212–6.[14]
Delouya G, Krishnan V, Bahary J-P, Larrive´e S, Taussky D. Analysis of the Cancer of the Prostate Risk Assessment to predict for biochem- ical failure after external beam radiotherapy or prostate seed brachytherapy. Urology 2014;84:629–33.
[15]
Vainshtein JM, Schipper M, Vance S, Feng FY, Olson KB, Hamstra DA. Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) prognostic tool for prediction of metastases and prostate cancer- specific mortality in patients treated with external beam radiation therapy. Am J Clin Oncol 2016;39:173–80.
[16]
Seong KT, Lim JH, Park CM, Kim HK, Park JY. External validation of the cancer of the prostate risk assessment-s score in Koreans undergoing radical prostatectomy. Korean J Urol 2013;54:433–6.
[17]
Punnen S, Freedland SJ, Presti JC, et al. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol 2014;65:1171–7.[18]
Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 2015;67:326–33.[19]
Tilki D, Mandel P, Schlomm T, et al. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. J Urol 2015;193:1970–5.[20]
Kitagawa Y, Hinotsu S, Shigehara K, et al. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade includ- ing bicalutamide: clinical application and validation. Int J Urol 2013;20:708–14.[21]
Akakura K, Tsuji H, Suzuki H, et al. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radio- therapy plus androgen deprivation therapy. Jpn J Clin Oncol 2014;44:360–5.[22]
Shiota M, Yokomizo A, Takeuchi A, et al. The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy. J Cancer Res Clin Oncol 2015;141:495–503.[23]
Yamaguchi Y, Hayashi Y, Ishizuya Y, et al. A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assess- ment (J-CAPRA) score. Jpn J Clin Oncol 2015;45:197–201.[24]
Cooperberg MR, Broering JM, Carroll PR. Risk assessment for pros- tate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009;101:878–87.[25]
Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straight- forward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011;117:5039–46.[26]
Cooperberg MR, Hinotsu S, Namiki M, et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009;27:4306–13.[27]
Cooperberg MR, Simko JP, Stone S, et al. Validation of a cell-cycle progression gene panel to improve risk-stratification in a contem- porary prostatectomy cohort. J Clin Oncol 2013;31:1428–34.[28]
Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersam- pling. Eur Urol 2014;66:550–60.E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 7 0 5 – 7 0 9
709